NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide.
Adequate balance sheet with concerning outlook.
Share Price & News
How has NanoString Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NSTG's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: NSTG underperformed the US Life Sciences industry which returned 19.7% over the past year.
Return vs Market: NSTG exceeded the US Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is NanoString Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StBearish: Analysts Just Cut Their NanoString Technologies, Inc. (NASDAQ:NSTG) Revenue and EPS estimates
4 months ago | Simply Wall StNanoString Technologies, Inc. Just Reported And Analysts Have Been Lifting Their Price Targets
5 months ago | Simply Wall StIs NanoString Technologies, Inc. (NASDAQ:NSTG) A Volatile Stock?
Is NanoString Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NSTG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NSTG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NSTG is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: NSTG is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NSTG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NSTG is overvalued based on its PB Ratio (9.8x) compared to the US Life Sciences industry average (5.8x).
How is NanoString Technologies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NSTG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NSTG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NSTG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NSTG's revenue (17.1% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: NSTG's revenue (17.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NSTG is forecast to be unprofitable in 3 years.
How has NanoString Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NSTG is currently unprofitable.
Growing Profit Margin: NSTG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NSTG is unprofitable, and losses have increased over the past 5 years at a rate of -9% per year.
Accelerating Growth: Unable to compare NSTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NSTG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (9.7%).
Return on Equity
High ROE: NSTG has a negative Return on Equity (-42.49%), as it is currently unprofitable.
How is NanoString Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: NSTG's short term assets ($317.2M) exceed its short term liabilities ($35.4M).
Long Term Liabilities: NSTG's short term assets ($317.2M) exceed its long term liabilities ($194.3M).
Debt to Equity History and Analysis
Debt Level: NSTG's debt to equity ratio (121.9%) is considered high.
Reducing Debt: NSTG's debt to equity ratio has increased from 96.7% to 121.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NSTG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NSTG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 17.9% each year
What is NanoString Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NSTG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NSTG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NSTG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NSTG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NSTG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brad Gray (43yo)
Mr. R. Bradley Gray, also known as Brad, has been the Chief Executive Officer and President of NanoString Technologies, Inc. since June 29, 2010. Mr. Gray worked at Genzyme Genetics, the diagnostic service ...
CEO Compensation Analysis
Compensation vs Market: Brad's total compensation ($USD7.29M) is above average for companies of similar size in the US market ($USD4.72M).
Compensation vs Earnings: Brad's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||10.08yrs||US$7.29m||0.27% $3.6m|
|Chief Financial Officer||2.5yrs||US$2.11m||no data|
|Senior Vice President of Corporate & Business Development||6.67yrs||US$1.46m||0.19% $2.5m|
|Senior Vice President of Sales & Marketing||3yrs||US$2.09m||0.00044% $5.8k|
|Chief Science Officer and Senior VP of Research & Development||8.25yrs||US$2.09m||0.15% $2.0m|
|Senior Vice President of Operations||0.75yr||no data||no data|
|Vice President of Investor Relations & Corporate Communications||3.83yrs||no data||no data|
|VP, General Counsel & Corporate Secretary||7.42yrs||no data||no data|
|Vice President of Human Resources||6.75yrs||no data||no data|
|Senior Vice President of Strategic Initiatives||0.75yr||US$896.35k||no data|
Experienced Management: NSTG's management team is seasoned and experienced (5.3 years average tenure).
|CEO, President & Director||10.08yrs||US$7.29m||0.27% $3.6m|
|Independent Chairman||10.5yrs||US$241.46k||0.085% $1.1m|
|Independent Director||3.17yrs||US$207.20k||0.0050% $66.1k|
|Independent Director||0.75yr||US$208.10k||no data|
|Independent Director||16yrs||US$207.48k||0.0050% $66.1k|
|Independent Director||5.33yrs||US$194.98k||0.0050% $66.1k|
|Independent Director||3.83yrs||US$195.98k||0.010% $132.1k|
|Independent Director||8yrs||US$212.25k||0.032% $415.5k|
|Member of Sequencing Advisory Board||no data||no data||no data|
Experienced Board: NSTG's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.6%.
NanoString Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NanoString Technologies, Inc.
- Ticker: NSTG
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.319b
- Shares outstanding: 37.73m
- Website: https://www.nanostring.com
Number of Employees
- NanoString Technologies, Inc.
- 530 Fairview Avenue North
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NSTG||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 2013|
|0F1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2013|
NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and pan cancer and 360 gene expression, CAR-T characterization, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, miRNA expression, human organ transplant, human and mouse metabolic pathway, and human and mouse fibrosis panels. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq molecular profiling system to determine and analyze gene sequences within biological samples. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/12 00:00|
|End of Day Share Price||2020/07/10 00:00|